Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal

Sandoz Japan President Shingo Iwamoto Sandoz is setting out to make aggressive investments in its biosimilar business in Japan after obtaining the distribution rights to Nichi-Iko Pharmaceutical’s Avastin (bevacizumab) follow-on, which will be launched later this month. Through in-licensing activities...read more